SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT02544204
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Juventas Therapeutics, Inc.
- Registry
-
NCT02544204
-
- Other papers using this trial's data
- SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial
- Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients With Peripheral Artery Disease (STOP-PAD) Trial: Six-Month Results
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT02544204. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
- Acronym
- STOP-PAD
- Condition
- Peripheral Arterial Disease
- Intervention (Biological)
- JVS-100
- Intervention (Biological)
- Placebo
- Lead sponsor
- Juventas Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct02544204- Content hash
8833358c9a12f885f4a2011b46d601eb0ccba1220e33881e8b1e134bdd6d5270